
Alberta's coal mine reclamation standards failing to protect water, fish: study
CALGARY — Alberta regulations meant to keep old coal mines from polluting streams and lakes are failing, suggests a study by government scientists.
The study says high levels of numerous contaminants are having grave outcomes for aquatic life and their ecosystems.
One of the authors, a former Alberta government scientist in charge of environmental monitoring, says the paper speaks to 'regulatory inaction.'
'These results suggest current reclamation practices and regulatory requirements for water quality and aquatic ecosystems are not meeting the desired objectives,' the authors write at the end of the report.
The peer-reviewed study is by three Alberta government scientists and the former government scientist, who is now an environmental consultant.
They took samples from rivers near three old coal mines south of Hinton, Alta., which are four kilometres from Jasper National Park at their closest point. The mines closed in the early 2000s.
The authors discovered some improvements to water quality since mining activities ended. But in rivers downstream from those mines, they found high concentrations of several pollutants in the water. In the Luscar Creek and Gregg River, for example, nickel ratios were 200 times higher downstream from the mines than in water upstream.
In the nearby McLeod River Basin, they determined selenium levels and other ions provide a 'persisting threat to water quality,' even though one mine has been nearly fully reclaimed and another is 60 per cent reclaimed.
The authors looked at the number of samples in which selenium concentrations exceeded Alberta's protection of aquatic life guideline, a limit the province uses to determine when contamination levels would likely cause harm to an ecosystem. At six locations, 98 to 100 per cent of testing samples found selenium concentrations exceeded that limit.
They write that elevated selenium levels have 'insidious' effects on certain fish and birds, because the substance is passed down from parents to offspring and presents in deformities and impairs their ability to reproduce. It is otherwise a naturally occurring element that's vital in small amounts.
The authors also note the McLeod River Basin is home to Athabasca Rainbow Trout, listed as endangered Canada's Species At Risk Act — a law created to protect and recover at-risk species. They write that the trout is likely to go extinct. More broadly, they write that a growing body of research shows 'reclamation and mitigation practices may not restore aquatic habitat or reverse ecological damage.'
Bill Donahue, one of the study's authors and a former chief of environmental monitoring for the Alberta government, said in an interview that the study demonstrates 'regulatory inaction.'
'The big lie is that Albertans seem to think that the regulator is going to look at what's submitted and, if those promises and requirements aren't met, then the company is going to have to fix it,' he said.
'Well, here's the paper that says that's not true.'
Donahue said he's unsure proper regulations can be created to reverse the impacts of coal mining, because there is little historical evidence companies have been able to do so after they've ended operations, no matter how much money they spend.
He also called the study a 'warning flag' for future coal projects in Alberta.
Earlier this year, the Alberta Energy Regulator granted an Australia-based coal company permission to start a controversial coal exploration on the eastern slopes of the Rockies, concluding the small-scale project likely won't have any effect on water quality downstream.
The regulator said at the time that it couldn't consider the possibility that the exploration permit might lead to a full-blown coal mine in the future.
Ryan Fournier, press secretary for Alberta's Environment Ministry, said the province has shared the study with the regulator and it's one of the reasons the province isn't allowing any more open-pit mines.
It's up to the regulator to decide if more monitoring or actions are needed in the bodies of water referenced in the study, Fournier said, adding selenium levels sometimes exceeded fish protection alert levels but there's currently no evidence of population decline.
'These results are also why any new mines will be required to either be underground mines or use advanced selenium management techniques and deploy state-of-the-art technology and monitoring to protect the surrounding environment,' he wrote in a statement.
The regulator said in a statement it's reviewing the findings.
Asked if it was aware of selenium concentrations in Luscar Creek or Gregg River, the regulator said it has a long-standing requirement for approval holders to reduce selenium concentrations to levels that don't affect the aquatic environment and it has tools to enforce regulatory compliance.
'Achievement of selenium reduction objectives is expected to progress over multiple years as mines advance towards reclamation,' it said.
This report by The Canadian Press was first published Aug. 1, 2025.
Matthew Scace, The Canadian Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
27 minutes ago
- Globe and Mail
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development. to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams. WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN) today announced that its artificial intelligence initiative, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model. Powered by the Databricks Data Intelligence Platform and backed by their innovative engineering teams, has begun curating a dataset focused on oncology. The dataset, aggregated with the initial virology dataset. aims to improve upon the accuracy of the alpha version of PredicTcell model. This next phase of development builds on recently published international patent application (WO 2025/129197), which outlines novel machine learning systems for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases. 'We have been extremely fortunate to work with such great organizations like Microsoft and Databricks to build the alpha version of our foundational AI model,' said Mittul Mehta, Chief Information Officer and Head of 'Oncology represents one of the most impactful areas for AI in drug discovery, given the complexity of the disease and the limited availability of high-quality datasets.' Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

National Post
8 hours ago
- National Post
Satellos to Present at Canaccord Genuity's 45th Annual Growth Conference
Article content TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the Canaccord Genuity's 45th Annual Growth Conference, taking place Aug. 13–14, 2025, at the InterContinental Boston. Article content Satellos management will present on Wed., Aug. 13, from 12:30 to 12:55 p.m. ET in Abigail Adams C and will participate in one-on-one meetings during the conference. Article content Article content Canaccord Genuity's 45th Annual Growth Conference Article content Format: Presentation and Article content webcast Article content Article content Date: Wed., Aug. 13 Article content Article content Time: 12:30 p.m. ET Article content Article content Location: InterContinental Boston Article content The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company's website, and a replay will be available following the presentation. Article content About Satellos Bioscience Inc. Article content Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, starting with DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Article content Article content Article content Article content Article content Contacts Article content Investors: Article content Liz Williams, CFO, Article content ir@ Article content Article content Media: Article content Article content


National Post
8 hours ago
- National Post
Your body fat percentage is killing you, not your BMI, study suggests
Data collected from the health survey were linked to death certificate records. The researchers looked at the 'mortality status' — alive, or deceased — of each participant after 15 years. Adults with a higher body-fat percentage (27 per cent or more in men; 44 per cent or more in women) were 1.78 times more likely to die from any cause than people with lower body fat percentages. Those with a high body-fat count were also 3.62 times more likely to die from heart disease. However, a BMI in the unhealthy range — 25 or higher — was not associated with a higher risk of death from any cause, compared with adults in the healthy BMI range. 'Now remember, using BMI did not flag any risk at all in this younger population, which isn't one we typically consider to be at high risk for heart disease,' the study's senior author, Dr. Frank Orlando, told CNN. 'Think of the interventions we can do to keep them healthy when we know this early. I think it's a game-changer for how we should look at body composition,' he said. The study used BIA technology decades old 'and that still had stronger associations with mortality when compared with the BMI,' the researchers wrote. 'Current BIA models provide reproducible results in less than one minute,' making their adoption easy for busy family medicine clinics, they said. 'For essentially the same price as a scale to weigh newborns or a machine to sterilize instruments a machine to reliably and validly assess body fat percentage will allow a practice to accurately target the patient who can benefit most from obesity and body fat reduction strategies to prevent a wide variety of diseases,' Mainous told Medscape. At-home bathroom scales, fitness apps and smartwatches have also started to incorporate BIA technology though they aren't as precise as office-based machines. A high waist circumference — more than 44 inches in men and more than 35 inches is women — which doesn't depend on height or weight also did better than BMI in predicting risks. The study has several limitations, including that it focused on mortality as the outcome. While 'this is the strongest and most definitive health outcome' the researchers didn't consider morbidity, meaning other health complications other than death. The authors are urging more and larger studies across different populations to determine healthy body fat percentage ranges, and at different ages. 'Once these standards are validated, it is likely that measuring BF% with BIA will become standard of care,' they said. 'These data will drive better discussions in the doctor's office as well as public health initiatives with the goal of improving the health of all.' Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our newsletters here.